Novartis have said it is not going forward with a new asthma drug, as the treatement failed its Phase 3 trials.
The company announced that the drug, called fevipiprant, did not meet its clinically relevant threshold for reduction in rates of moderate-to-severe exacerbation compared to placebo, for either of the doses, when evaluated over a treatment period of one year.
This follows the results of another failed Phase 3 trial of fevipiprant, a few weeks back, in patients with mild-to-moderate asthma.